Sol-Gel Technologies (4SG) Price & Analysis

0 Followers

4SG Stock Chart & Stats

€67.00

-€3.00(-4.29%)

At close: Jul 28 4:00 PM EDT

€67.00

-€3.00(-4.29%)

Day’s Range― - ―

52-Week Range€12.50 - €82.00

Previous CloseN/A

Volume0.00

Average Volume (3M)15.00

Market Cap

€239.00M

Enterprise Value€172.77

Total Cash (Recent Filing)€30.47M

Total Debt (Recent Filing)€1.39M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

May 07, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding3,268,991

10 Day Avg. Volume46

30 Day Avg. Volume15

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)5.15

Price to Sales (P/S)6.06

P/FCF Ratio426.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€166.61

Price Target Upside148.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-7.2

Revenue Forecast (FY)€153.30K

Bulls Say, Bears Say

Bulls Say

Extended IP ProtectionExtending a method-of-use patent for SGT-610 to 2044 secures long-term exclusivity for the lead candidate, protecting future sales and licensing economics. Durable patent life lowers generic risk, supports partner interest, and increases the asset's value during commercialization and royalty phases.

Sharp 2025 Revenue ReboundA dramatic revenue rebound with gross profit nearly equal to revenue in 2025 signals product-level economics and demand recovery. If sustained, this trend supports scalable commercial margins and reduces reliance on financing for operations, underpinning longer-term viability of the dermatology franchise.

Improved Cash Runway From FinancingA $33.1M oversubscribed offering meaningfully extends liquidity into Q1 2028, lowering near-term funding risk. This capital buffer enables completion of pivotal trials, commercialization activities and partner deals without immediate dilution pressure, supporting the company’s multi-year development and launch plans.

Bears Say

Eroding Equity BaseCumulative losses have materially reduced shareholders' equity over several years, weakening the balance sheet cushion against operational shocks. A smaller equity base limits financial flexibility, intensifies dilution risk from future financings, and makes the company more sensitive to setbacks in commercialization or trials.

Historic Cash Burn VolatilityPrior years of heavy operating cash burn demonstrate a history of funding dependence that could recur if revenue momentum falters. This volatility raises the probability of additional capital raises, which can dilute shareholders and disrupt execution; sustaining positive cash flow is required to make recent improvements durable.

Persistent Operating Losses And Margin VolatilityDespite revenue recovery, the company remained loss-making in 2025 with volatile margins historically, indicating profitability is not yet established. Ongoing negative earnings constrain free cash generation and raise execution risk for commercialization and R&D, meaning sustained margin improvement is required for durable financial health.

Sol-Gel Technologies News

Maintains Buy Rating and $184 Price Target on SGT-610’s Promising Gorlin Syndrome Opportunity

Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on Sol-Gel Technologies and keeping the price target...

3h ago

SLGL

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq:VRTX) agreed to pay...

26d ago

PTN

CRNX

Sol-Gel Technologies initiated with an Outperform at Mizuho

Mizuho initiated coverage of Sol-Gel Technologies (SLGL) with an Outperform rating and $285 price target The firm sees...

2M ago

SLGL

Sol-Gel Technologies initiated with a Buy at TD Cowen

TD Cowen analyst Stacy Ku initiated coverage of Sol-Gel Technologies (SLGL) with a Buy rating and no price...

3M ago

SLGL

Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target

Sol-Gel Technologies, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Dolezal from...

3M ago

SLGL

Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year

Reports Q1 revenue $108,000 vs. $1.03M last year. Mori Arkin, executive chairman of Sol-Gel, stated: “The first quarter...

3M ago

SLGL

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

Sol-Gel Technologies ( ($SLGL) ) just unveiled an announcement. In the first quarter of 2026, Sol-Gel Technologies secured...

3M ago

SLGL

Sol-Gel Technologies Prices $33.1 Million Oversubscribed Equity Offering to Advance SGT-610

Sol-Gel Technologies ( ($SLGL) ) has provided an update. On March 23, 2026, Sol-Gel Technologies entered into an...

5M ago

SLGL

Sol-Gel Technologies 459K share Spot Secondary priced at $72.00

TD Cowen and LifeSci Capital are acting as joint book running managers for the offering. Published first on...

5M ago

SLGL

Sol Gel Technologies trading resumes

09:48 EDT Sol Gel Technologies trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

5M ago

SLGL

Sol Gel Technologies trading halted, volatility trading pause

09:38 EDT Sol Gel Technologies trading halted, volatility trading pause Published first on TheFly – the ultimate source...

5M ago

SLGL

Sol-Gel Technologies: Upside-Driven Buy on SGT-610’s Orphan Gorlin Syndrome Opportunity and Repriced Peak Sales Potential

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Sol-Gel Technologies, with...

7M ago

SLGL

Sol-Gel Technologies price target raised to $110 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Sol-Gel Technologies (SLGL) to $110 from $50 and keeps a...

7M ago

SLGL

Sol-Gel: SGT-610 as Core Value Driver Underpins $50 Target and Buy Rating Despite Pipeline Setbacks

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sol-Gel Technologies, with...

8M ago

SLGL

4SG FAQ

What was Sol-Gel Technologies’s price range in the past 12 months?

Sol-Gel Technologies lowest stock price was €12.50 and its highest was €82.00 in the past 12 months.

What is Sol-Gel Technologies’s market cap?

Sol-Gel Technologies’s market cap is €239.00M.

When is Sol-Gel Technologies’s upcoming earnings report date?

Sol-Gel Technologies’s upcoming earnings report date is May 07, 2027 which is in 263 days.

How were Sol-Gel Technologies’s earnings last quarter?

Currently, no data Available

Is Sol-Gel Technologies overvalued?

According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sol-Gel Technologies pay dividends?

Sol-Gel Technologies does not currently pay dividends.

What is Sol-Gel Technologies’s EPS estimate?

Sol-Gel Technologies’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sol-Gel Technologies have?

Sol-Gel Technologies has 3,268,991 shares outstanding.

What happened to Sol-Gel Technologies’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Sol-Gel Technologies?

Currently, no hedge funds are holding shares in DE:4SG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sol-Gel Technologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

116.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sol-Gel Technologies

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

Sol-Gel Technologies (4SG) Earnings & Revenues

Historic Earnings Reports

4SG Stock 12 Month Forecast

Average Price Target

€166.61

▲(148.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"€9","128":"€128","247":"€247","68.5":"€68.5","187.5":"€187.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":246.0319785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€246.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":166.61112930000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€166.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.959711,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€94.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,68.5,128,187.5,247],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,85.38707526923076,98.77415053846154,112.16122580769232,125.54830107692308,138.93537634615384,152.32245161538464,165.7095268846154,179.09660215384616,192.48367742307693,205.8707526923077,219.25782796153848,232.64490323076924,{"y":246.0319785,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,79.27777917692308,86.55555835384615,93.83333753076923,101.1111167076923,108.38889588461538,115.66667506153847,122.94445423846155,130.2222334153846,137.5000125923077,144.77779176923076,152.05557094615386,159.33335012307694,{"y":166.61112930000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,73.76613161538461,75.53226323076923,77.29839484615384,79.06452646153846,80.83065807692307,82.5967896923077,84.3629213076923,86.12905292307693,87.89518453846154,89.66131615384616,91.42744776923077,93.19357938461539,{"y":94.959711,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.6,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.7,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >